Tender Details

Country: USA
Summary: Japanese Encephalitis Vaccine (Jev)
UST Ref No: 82003429
Deadline: 21 May 2023
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: SPE2DP-23-R-0001
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Description
The Defense Logistics Agency Troop Support is seeking sources capable of providing the Japanese Encephalitis Vaccine (JEV). DLA Troop Support is contemplating awarding a one-year base and a one year option, indefinite quantity contract for the JEV. The estimated annual quantity to be ordered is 200,000 doses minimum and 300,000 doses maximum for the base year and 160,000 doses minimum and 260,000 doses maximum for option year 1. However, the quantity may increase or decrease as the Services requirements change.
The vaccine shall be purified, inactivated, Vero Cell culture derived, contain no stabilizers, Thimerosal/Preservative free, Latex free, licensed by the Food and Drug Administration (FDA), suitable for intramuscular administration and intended for active immunization against Japanese Encephalitis disease. The vaccine shall be a sterile 0.5 ml suspension in a pre-filled syringe (Type 1 glass) with a plunger stopper (chlorobutyl elastomer) with or without a separate needle. The vaccine must be approved by the FDA for administration to persons 2 months of age and up.
Must have FDA approval to sell the JEV before award of the contract.
If your firm currently manufactures or distributes the JEV, please provide information with respect to the following:

a) Place of manufactureb) Estimated annual capacityc) FDA registrationd) Product name and description including description of any special featurese) Current unit sale pricef) Estimated inventory level and storage requirements

*** NEW PRODUCTS UNDER DEVELOPMENT***

For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture the JEV or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support.

Data ob...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Japanese Encephalitis Vaccine (Jev) - USA Tender

The DEPT OF DEFENSE, a Government sector organization in USA, has announced a new tender for Japanese Encephalitis Vaccine (Jev). This tender is published on USARFP under UST Ref No: 82003429 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2023-05-21.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.